FrancophonIA/ELRC3.0 huggingface dataset:
English: - If your newborn gets any side effects, talk to your baby's doctor.
Estonian: - Kui teie vastsündinul tekib ükskõik milline kõrvaltoime, pidage nõu oma imiku arstiga.
English: Treatment with caffeine citrate should be initiated under the supervision of a physician experienced in neonatal intensive care.
Estonian: Kofeiintsitraadiga võib alustada ravi vastsündinute intensiivravis kogenud arsti järelevalve all.
English: If your newborn gets any side effects, talk to your baby's doctor.
Estonian: Kui teie vastsündinul tekib ükskõik milline kõrvaltoime, pidage nõu oma imiku arstiga.
English: • If your newborn has kidney or liver problems
Estonian: • kui teie vastsündinul on neeru- või maksafunktsiooni häireid
English: Caffeine may suppress erythropoietin synthesis and hence reduce haemoglobin concentration with prolonged treatment.
Estonian: Pikaajalise ravi korral võib kofeiin pärssida erütropoetiini sünteesi ja seetõttu vähendada hemoglobiinikontsentratsiooni.
English: A reduced daily maintenance dose of caffeine citrate is required and the dose should be guided by plasma caffeine measurements.
Estonian: Kofeiintsitraadi säilitusannust päeva kohta tuleb vähendada ja annuse määramisel juhinduda kofeiini kontsentratsioonidest plasmas.
English: Peyona 20 mg/ml solution for infusion and oral solution
Estonian: Peyona 20 mg/ml infusioonilahus ja suukaudne lahus
English: The known pharmacology and toxicology of caffeine and other methylxanthines predict the likely adverse reactions to caffeine citrate.
Estonian: Kofeiintsitraadi tõenäolisi kõrvaltoimeid võib prognoosida kofeiini ja teiste metüülksantiinide teadaoleva farmakoloogia ja toksikoloogia põhjal.
English: Hepatic cytochrome P450 1A2 (CYP1A2) is involved in caffeine biotransformation in older individuals.
Estonian: Vanematel patsientidel osaleb kofeiini biotransformatsioonis maksa tsütokroom P450 1A2 (CYP1A2).
English: The dose expressed as caffeine base is one-half the dose when expressed as caffeine citrate (20 mg caffeine citrate are equivalent to 10 mg caffeine base).
Estonian: Kofeiinina väljendatud annus moodustab poole kofeiintsitraadina väljendatud annusest (20 mg kofeiintsitraati vastab 10 mg kofeiinile).
English: Caffeine has a prolonged half-life in premature newborn infants and there is potential for accumulation which may necessitate monitoring infants treated for an extended period (see section
Estonian: Kofeiini poolväärtusaeg on enneaegsetel vastsündinutel pikenenud ja see võib nende kehasse koguneda, mistõttu pikemaajalist ravi saavaid imikuid võib osutuda vajalikuks jälgida (vt lõik 5.2).
English: As for all preterm infants, those treated with caffeine citrate should be carefully monitored for the development of necrotising enterocolitis (see section
Estonian: Nagu kõiki enneaegseid imikuid, tuleb kofeiintsitraadiga ravitavaid imikuid hoolikalt jälgida nekrotiseeriva enterokoliidi tekkimise suhtes (vt lõik 4.4).
English: The active substance is caffeine citrate.
Estonian: Toimeaine on kofeiintsitraat.
English: Peyona is a solution for infusion and oral solution.
Estonian: Peyona on infusioonilahus ja suukaudne lahus.
English: The starting dose is 20 mg per kg body weight (equivalent to 1 ml per kg body weight).
Estonian: Algannus on 20 mg kehakaalu kilogrammi kohta (vastab 1 ml-le kehakaalu kilogrammi kohta).
English: Dose of caffeine citrate (Volume)
Estonian: Kofeiintsitraadi annus (mahult)
English: Loading dose 1.0 ml/kg body weight
Estonian: 1,0 ml kehakaalu kg kohta
English: Citric acid monohydrate, sodium citrate, water for injections.
Estonian: Sidrunhappe monohüdraat, naatriumtsitraat, süstevesi.
English: 20 mg/kg body weight Intravenous infusion (over 30 minutes)
Estonian: Intravenoosne infusioon (30 minuti jooksul)
English: Treatment of primary apnoea of premature newborns.
Estonian: Primaarse apnoe ravi enneaegsetel vastsündinutel.
English: Endotracheal tube
Estonian: Endotrahheaalne intubatsioon
English: - That Peyona is for the treatment of primary apnoea - That treatment with Peyona must be provided in a neonatal intensive care unit and initiated and supervised by a physician experienced in neonatal intensive care - Details of the loading and maintenance dosages and that caffeine may accumulate in premature newborn infants because of its long half-life.
Estonian: - Peyona ravi viiakse läbi vastsündinute intensiivravi osakonnas ning seda alustab ja juhib vastsündinute intensiivravi kogemusega arst.
English: Peyona 20 mg/ml solution for infusion and oral solution Caffeine citrate (equivalent to 10 mg/ml of caffeine base) IV/oral use
Estonian: Peyona 20 mg/ml infusioonilahus ja suukaudne lahus Kofeiintsitraat (vastab 10 mg/ml kofeiinile) i.v./suukaudne
English: After opening the ampoule, the medicinal product should be used immediately.
Estonian: Pärast lahjendamist aseptilisel meetodil tuleb ravim kohe ära kasutada.
English: - That the medicinal product should be used immediately after opening the ampoule and unused portions left in the ampoule should be discarded - That baseline plasma levels may need measuring because of an increased risk of toxicity if o The neonate has been previously treated with theophylline o The mother has been consuming large amounts of caffeine prior to delivery or breast feeding - That caffeine and theophylline should not be used concurrently - That if caffeine and doxapram are used concurrently, the patient should be closely monitored - That additional plasma caffeine monitoring and dosage adjustment may be necessary in at risk situations such as preterm infants: o With cholestatic hepatitis o With significant renal impairment o With seizure disorders o With cardiac disease o less than 28 weeks gestational age and/or body weight <1000g particularly when receiving parenteral nutrition o with co-administration of medicinal products known to interfere with caffeine metabolism - That cardiac disorders (including arrhythmias) may arise in newborn infants with pre-existing cardiac disease - That all suspected adverse reactions should be reported in accordance with national reporting requirements - In particular, if convulsions, seizures, necrotising enterocolitis, symptoms and signs of caffeine withdrawal, medically abnormal decrease in infant weight gain or interactions with other medicines are suspected as being associated with the use of caffeine citrate, these should be reported to <insert local name and address of Chiesi Farmaceutici S.p.A.>
Estonian: - Täiendav kofeiini sisalduse jälgimine ja annuste kohandamine võib olla vajalik riskiolukordades, nagu näiteks vastsündinud järgmiste seisunditega: o kolestaatiline hepatiit, o märkimisväärne neerupuudulikkus, o krampidega kulgev haigus, o südamehaigus, o gestatsioonivanus alla 28 nädala ja/või kehakaal <1000 g, eelkõige parenteraalse toitumise korral, o samaaegselt manustatakse ravimeid, mis teadaolevalt mõjutavad kofeiini ainevahetust.
English: Peyona 20 mg/ml solution for infusion and oral solution Caffeine citrate (equivalent to 10 mg/ml of caffeine base)
Estonian: Peyona 20 mg/ml infusioonilahus ja suukaudne lahus Kofeiintsitraat (vastab 10 mg/ml kofeiinile)
English: Peyona should be inspected visually for particulate matter and discoloration prior to administration.
Estonian: Peyonat tuleb enne manustamist osakeste ja värvuse muutuse suhtes visuaalselt kontrollida.
English: Caffeine citrate should be administered with caution in preterm newborn infants with impaired renal or hepatic function.
Estonian: Kofeiintsitraadi manustamisel neeru- või maksafunktsiooni kahjustusega enneaegsetele vastsündinutele peab olema ettevaatlik.
English: Plasma concentrations of caffeine may need to be monitored periodically throughout treatment in cases of incomplete clinical response or signs of toxicity.
Estonian: Puuduliku ravivastuse või toksilisuse nähtude korral võib osutuda vajalikuks jälgida kofeiini kontsentratsioone plasmas perioodiliselt kogu ravi vältel.
English: This medicine may increase the risk for serious intestinal disease with bloody stools (necrotising enterocolitis) when administered with medicines used to treat gastric disease (such as antihistamine H2 receptor blockers or proton-pump inhibitors that reduces gastric acid secretion).
Estonian: Selle ravimi manustamine koos maohaiguse ravimitega (nt antihistamiini H2 retseptori blokaatorid või prootonpumba inhibiitorid, mis vähendavad maohappe eritumist) võib suurendada verise väljaheitega tõsise soolehaiguse (nekrotiseeriv enterokoliit) tekkimise riski.
English: Caffeine citrate can be administered by intravenous infusion and by the oral route.
Estonian: Kofeiintsitraati manustatakse veeniinfusiooni teel või suu kaudu.
English: Non-clinical data revealed no major hazard for humans based on studies of repeated dose toxicity of caffeine.
Estonian: Kofeiini korduvtoksilisuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Irritability, jitteriness, restlessness, brain injury
Estonian: Närvisüsteemi häired krambid aeg-ajalt ärrituvus, närvilisus, rahutus, ajukahjustus teadmata
English: Each 3 ml ampoule contains 60 mg caffeine citrate (equivalent to 30 mg of caffeine base).
Estonian: Üks 3 ml ampull sisaldab 60 mg kofeiintsitraati (mis vastab 30 mg/ml kofeiinalusele).
English: Inter-conversion between caffeine and theophylline occurs in preterm newborn infants.
Estonian: Enneaegsetel vastsündinutel esineb kofeiini ja teofülliini vastastikust muundumist.
English: Your newborn may experience fever, rapid breathing (tachypnoea), jitteriness, muscular tremor vomiting, high blood levels of sugar (hyperglycemia), low blood levels of potassium (hypokalaemia), high blood levels of certain chemicals (urea), elevated number of certain cells (leukocyte) in blood and seizures if he/she receives more caffeine citrate than he/she should.
Estonian: (hüperglükeemia), vere kaaliumitaseme langus (hüpokaleemia), teatavate keemiliste ainete (uurea) taseme tõus, teatavate vererakkude (leukotsüüdid) arvu suurenemine ja krambihood.
English: Plasma caffeine concentrations have been shown to decrease after exchange transfusion.
Estonian: Pärast verevahetusülekannet on kofeiini tasemed plasmas vähenenud.
English: Arrhythmia
Estonian: Imendumine
English: 5 mg/kg body weight Intravenous infusion (over 10 minutes) or by oral administration
Estonian: Intravenoosne infusioon (10 minuti jooksul) või suukaudse manustamise teel
English: Any unused portion left in the ampoule should be discarded.
Estonian: Ampulli jäänud jäägid tuleb ära visata.
English: Hypoglycaemia, failure to thrive, feeding intolerance
Estonian: Ainevahetus- ja toitumishäired hüperglükeemia sage hüpoglükeemia, kasvupeetus, toidutalumatus teadmata
English: Caffeine has been shown to increase heart rate, left ventricular output, and stroke volume in published studies.
Estonian: Kofeiin on suurendanud avaldatud uuringute andmeil südame löögisagedust, vasaku vatsakese minutimahtu ja löögimahtu.
English: Extreme caution must be exercised if caffeine citrate is used in newborns with seizure disorders.
Estonian: Kofeiintsitraadi kasutamisel krambihäiretega vastsündinutel peab olema äärmiselt ettevaatlik.
English: Each ml contains 20 mg caffeine citrate (equivalent to 10 mg/ml of caffeine base).
Estonian: 1 ml sisaldab 20 mg kofeiintsitraati (mis vastab 10 mg/ml kofeiinalusele).
English: Hepatic and renal impairment
Estonian: Südame ja veresoonkonna nähud
English: There is evidence that caffeine causes tachyarrhythmias in susceptible individuals.
Estonian: Tundlikel inimestel on kofeiin põhjustanud tahhüarütmiaid.
English: The solution must not be used if it is discoloured or foreign particulate matter is present.
Estonian: Lahust, mis on värvi muutnud või sisaldab võõrosakesi, ei tohi kasutada.
English: Chiesi Pharmaceuticals B.V. Tel: +31 88 501 64 00
Estonian: Tel: +31 88 501 64 00
English: Each 1 ml ampoule contains 20 mg caffeine citrate (equivalent to 10 mg of caffeine base).
Estonian: Üks 1 ml ampull sisaldab 20 mg kofeiintsitraati (mis vastab 10 mg/ml kofeiinalusele).
English: − infants receiving co-administration of medicinal products known to interfere with caffeine metabolism (see section 4.5)
Estonian: − imikud, kellele manustatakse samal ajal ravimeid, mis teadaolevalt häirivad kofeiini metabolismi
English: Each ml contains 20 mg caffeine citrate (equivalent to 10 mg caffeine).
Estonian: 1 ml sisaldab 20 mg kofeiintsitraati (mis vastab 10 mg kofeiinile).
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Vaniqa on 20 March 2001.
Estonian: Euroopa Komisjon andis Vaniqa müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 20. Märtsil 2001.
English: Vaniqa eflornithine
Estonian: Vaniqa eflornitiin
English: Continued treatment is needed to maintain the beneficial effects and may lead to further improvement.
Estonian: Kasuliku toime säilitamiseks on vaja ravi jätkata ja see võib paranemist soodustada.
English: The full EPAR for Vaniqa can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Vaniqa kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Vaniqa should be stopped if no improvements are noticed within four months of starting treatment.
Estonian: Ravi Vaniqaga tuleb peatada, kui nelja kuu jooksul pärast ravi algust ei ole ilmnenud paranemist.
English: When this enzyme is blocked, the growth of hair is slowed down.
Estonian: Kui ensüüm blokeeritakse, karvakasv aeglustub.
English: Vaniqa is a white cream that contains the active substance eflornithine (115 mg).
Estonian: Vaniqa on valge kreem, mille toimeaine on eflornitiin (115 mg).
English: In both studies, significant improvement was seen with Vaniqa compared with placebo.
Estonian: Mõlemas uuringus täheldati Vaniqa kasutamisel märkimisväärset paranemist võrrelduna platseeboga.
English: Vaniqa is applied to clean and dry affected areas of the face and under the chin twice a day (at least eight hours apart).
Estonian: Vaniqat määritakse kaks korda päevas kuivadele ja puhastele haigusest mõjutatud piirkondadele näol ja lõua all, jättes kahe manustamiskorra vahele vähemalt kaheksa tundi.
English: Vaniqa has been studied in two clinical trials involving 596 women treated for up to 24 weeks with Vaniqa or placebo (a dummy treatment, in this case the cream without any active substance).
Estonian: Vaniqa toimet uuriti kahes kliinilises uuringus, milles osales 596 naist, keda raviti kuni 24 nädala jooksul Vaniqaga või platseeboga (näiv ravim, kõnealusel juhul toimeaineta kreem).
English: Improvement was seen as early as eight weeks after starting treatment.
Estonian: Paranemist võis märgata juba kaheksa nädala möödumisel pärast ravi alustamist.
English: Vaniqa should not be used in people who may be hypersensitive (allergic) to eflornithine or any of the other ingredients.
Estonian: Vaniqat ei tohi kasutada patsiendid, kes võivad olla eflornitiini või selle ravimi mis tahes muu koostisosa suhtes ülitundlikud (allergilised).
English: The CHMP decided that Vaniqa's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Vaniqa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Women using Vaniqa may still need to use other means to remove hair (plucking, shaving).
Estonian: Vaniqa ravi saavatel naistel võib olla vaja kasutada siiski ka teisi karvaeemaldamisvahendeid (väljakitkumine, raseerimine).
English: Other information about Vaniqa
Estonian: Muu teave Vaniqa kohta
English: For more information about treatment with Vaniqa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Vaniqaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vaniqa.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The effectiveness of the treatment was assessed at the end of the study by a doctor who graded the hirsutism as ‘clear/almost clear', ‘marked improvement', ‘improved' or ‘no improvement/worse', 48 hours after women had shaved the treated areas of the face and under the chin.
Estonian: Uuringu lõpus hindas ravi efektiivsust arst, kes 48 tunni pärast, kui patsient oli näo ja lõuaaluse ravitud piirkondi raseerinud, iseloomustas hirsutismi skaalal „sile / peaaegu sile“, „märkimisväärselt paranenud“, „paranenud“ või „ei ole paranenud / on halvenenud“.
English: Improvements may be noticed within eight weeks of starting treatment.
Estonian: Paranemine hakkab ilmnema kaheksa nädala jooksul pärast ravi alustamist.
English: The most common side effect with Vaniqa (seen in more than 1 patient in 10) is acne.
Estonian: Vaniqa kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on akne.
English: Vaniqa is used for the treatment of facial hirsutism in women.
Estonian: Vaniqat kasutatakse täiskasvanud naiste näonaha hirsutismi raviks.
English: The active substance in Vaniqa, eflornithine, works by blocking the action of an enzyme called ornithine decarboxylase.
Estonian: Vaniqa toimeaine eflornitiin blokeerib ensüümi ornitiin-dekarboksülaasi toime.
English: What is the risk associated with Vaniqa?
Estonian: Mis riskid Vaniqaga kaasnevad?
English: This is a summary of the European public assessment report (EPAR) for Vaniqa.
Estonian: Käesolev dokument on ravimi Vaniqa Euroopa avaliku hindamisaruande kokkuvõte.
English: When the results were combined, a successful outcome (graded as ‘clear/almost clear' or ‘marked improvement') was seen in 35% of the women treated with Vaniqa, compared with 9% of those treated with placebo.
Estonian: Kui uuringute tulemused ühendati, hinnati Vaniqaga ravitud naiste naharavi edukaks 35% juhtudest (hinnangud „sile /peaaegu sile“ või „märkimisväärselt paranenud“), platseeborühmas oli vastav näitaja 9%.
English: It is applied in a thin layer and rubbed in thoroughly.
Estonian: Kreem määritakse õhukese kihina ja hõõrutakse hoolikalt nahasse.
English: This enzyme is found in the bulb of the hair follicle where it controls hair production.
Estonian: Seda ensüümi esineb karvanääpsu karvasibulas, kus see reguleerib karva kasvamist.
English: For the full list of all the side effects reported with Vaniqa, see the package leaflet.
Estonian: Vaniqa kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Facial hirsutism is excessive growth on the face of coarse hair, often in a male pattern.
Estonian: Näonaha hirsutism on tugevate karvade vohamine näol, moodustades sageli meheliku karvkatte.
English: How has Vaniqa been studied?
Estonian: Kuidas Vaniqat uuriti?
English: How is Vaniqa used?
Estonian: Kuidas Vaniqat kasutatakse?
English: What is Vaniqa used for?
Estonian: Milleks Vaniqat kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Vaniqa on retseptiravim.
English: What benefit has Vaniqa shown during the studies?
Estonian: Milles seisneb uuringute põhjal Vaniqa kasulikkus?
English: How does Vaniqa work?
Estonian: Kuidas Vaniqa toimib?
English: 3 x 30 tablets
Estonian: 3 x 30 tabletid
English: 30 tablets
Estonian: 30 tabletid
English: Strength Pharmaceutical form Route of administration
Estonian: Ravimvorm Manustamistee Sisepakendi iseloomustus
English: The success rates in the second study were similar.
Estonian: Teise uuringu edukuse määrad olid sarnased.
English: This summary was last updated in July 2013.
Estonian: Kokkuvõtte viimane uuendus: juuli 2013.
English: Treatment may then be continued at the same dose given once a day.
Estonian: Seejärel võib ravi jätkata sama annuse manustamisega üks kord ööpäevas.
English: Oclaticinib
Estonian: Oklatsitiniib
English: One study involved 220 dogs and the second involved 299 dogs.
Estonian: Esimeses uuringus osales 220 ja teises 299 koera.
English: Hands should be washed after handling the tablets.
Estonian: Pärast tablettide manustamist tuleb käsi pesta.
English: Treatment should be started at a dose of 0.4 - 0.6 mg per kilogram bodyweight twice a day for up to two weeks.
Estonian: Ravi tuleb alustada annusega 0,40,6 mg kehamassi kg kohta kaks korda ööpäevas kuni kaks nädalat.
English: Apoquel tablets are available in three different strengths (3.5 mg, 5.4 mg and 16 mg) to cover a range of dog weights.
Estonian: Apoqueli tablette turustatakse kolme erineva tugevusega (3,5 mg, 5,4 mg ja 16 mg) erineva kaaluga koerte jaoks.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Apoquel exceed the risks for the approved indications and recommended that Apoquel be given a marketing authorisation.
Estonian: Veterinaarravimite komitee jõudis järeldusele, et Apoqueli kasulikkus ületab heaks kiidetud näidustuste puhul riskid ja soovitas Apoquelile anda müügiloa.
English: For the appropriate strength of tablets and number of tablets to be given, see the dosage table in the package leaflet.
Estonian: Tablettide sobivat tugevust ja manustatavate tablettide arvu vaadake pakendi infolehe annustamistabelist.
English: The most common side effects were diarrhoea, vomiting and loss of appetite in decreasing order of frequency.
Estonian: Kõige sagedamini esinevad kõrvalnähud olid kõhulahtisus, oksendamine ja vähenenud söögiisu, mille esinemissagedus järjest vähenes.
English: The active substance in Apoquel, oclacitinib, is an immunomodulator (a medicine that changes the activity of the immune system) that works by blocking the action of enzymes known as Janus kinases.
Estonian: Apoqueli toimeaine oklatsitiniib on immunomodulaator (ravim, mis muudab immuunsüsteemi toimimist), mis blokeerib Janus kinaasidena tuntud ensüümide toime.
English: In case of accidental ingestion, medical advice should be sought immediately and the package leaflet or the label shown to the doctor.
Estonian: Juhuslikul ravimi allaneelamisel pöörduge viivitamatult arsti poole ja näidake talle pakendi infolehte või etiketti.
English: By blocking the enzymes, Apoquel reduces the inflammation and itchiness associated with the disease.
Estonian: Ensüüme blokeerides vähendab Apoquel haigusega kaasnevat põletikku ja sügelust.
English: Other information about Apoquel:
Estonian: Muu teave Apoqueli kohta
English: Apoquel is a veterinary medicine that contains the active substance oclaticinib.
Estonian: Apoquel on veterinaarravim, mille toimeaine on oklatsitiniib.
English: In both, Apoquel was compared with placebo.
Estonian: Mõlemas võrreldi Apoqueli platseeboga.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Apoquel on 12/09/2013.
Estonian: Euroopa Komisjon andis Apoquelile müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 12. septembril 2013.Teave selle kohta, kas toode on retseptiravim, on esitatud etiketil/välispakendil.
English: What is Apoquel?
Estonian: Mis on Apoquel?
English: These enzymes play an important role in the processes of inflammation and itchiness including those involved in allergic dermatitis and atopic dermatitis in dogs.
Estonian: Nendel ensüümidel on põletikuprotsessides ja sügelusel oluline roll, sealhulgas allergilise ja atoopilise dermatiidi puhul koertel.
English: Studies in atopic dermatitis also used assessment of skin lesions on a score known as the canine atopic dermatitis extent and severity index (CADESI).
Estonian: Atoopilise dermatiidi uuringutes hinnati nahakahjustusi ka koerlaste atoopilise dermatiidi ulatuse ja raskuse indeksi (canine atopic dermatitis extent and severity index ehk CADESI) järgi.
English: What is the risk associated with Apoquel?
Estonian: Mis riskid Apoqueliga kaasnevad?
English: Why has Apoquel been approved?
Estonian: Miks Apoquel heaks kiideti?